Abstract
Introduction The clinical impact of COVID-19 has not been established in the dialysis population. We evaluated the trajectories of clinical and laboratory parameters in hemodialysis (HD) patients.
Methods We used data from adult HD patients treated at an integrated kidney disease company who received a RT-PCR test to investigate suspicion of a SARS-CoV-2 infection between 01 May and 01 Sep 2020. Nonparametric smoothing splines were used to fit data for individual trajectories and estimate the mean change over time in patients testing positive or negative for SARS-CoV-2 and those who survived or died within 30 days of first suspicion or positive test date. For each clinical parameter of interest, the difference in average daily changes between COVID-19 positive versus negative group and COVID-19 survivor versus non-survivor group was estimated by fitting a linear mixed effects model based on measurements in the 14 days before (i.e., day-14 to day 0) day 0.
Results There were 12,836 HD patients with a suspicion of COVID-19 who received RT-PCR testing (8,895 SARS-CoV-2 positive). We observed significantly different trends (p<0.05) in pre-HD systolic blood pressure (SBP), pre-HD pulse rate, body temperature, ferritin, lymphocytes, albumin, and interdialytic weight gain (IDWG) between COVID-19 positive and negative patient. For COVID-19 positive group, we observed significantly different clinical trends (p<0.05) in pre-HD pulse rate, lymphocytes, albumin and neutrophil-lymphocyte ratio (NLR) between survivors and non-survivors. We also observed that, in the group of survivors, most clinical parameters returned to pre-COVID-19 levels within 60-90 days.
Conclusion We observed unique temporal trends in various clinical and laboratory parameters among HD patients who tested positive versus negative for SARS-CoV-2 infection and those who survived the infection versus those who died. These trends can help to define the physiological disturbances that characterize the onset and course of COVID-19 in HD patients
Competing Interest Statement
SC is a student at Maastricht University Medical Center. SC, RL, YJ, JL, CM, AW, LN, JH, LU and FM are employees of Fresenius Medical Care. PK is an employee of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. SC, PK, JH, LU, FM have share options/ownership in Fresenius Medical Care. PK is an inventor on multiple patents in the field of dialysis and is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research. FM has directorships in the Fresenius Medical Care Management Board, Goldfinch Bio, and Vifor Fresenius Medical Care Renal Pharma. SL, YW and JPK has no relevant conflicts of interest to disclose.
Funding Statement
Analysis and manuscript composition were supported by Fresenius Medical Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was performed under a protocol reviewed by New England Institutional Review Board (Needham Heights, MA, United States; Version 1.0 NEIRB# 17-1376378-1) who determined this analysis of existing patient data that was de-identified by the investigator was exempt and did not require informed consent. This analysis was conducted in adherence with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This analysis used data from patients treated at an integrated kidney disease company in the United States (Fresenius Medical Care North America). The data was deidentified by the investigator and is restricted to use by authorized individuals. The deidentified dataset is not publicly available.
